MAINZ, Germany, March 6, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the full year and fourth quarter 2023 on Wednesday, March 20, 2024. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. ET (2:00 p.m. CET) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update. To access the live conference call via telephone, please register via ...

The pharma industry has developed some real blockbusters between novel vaccines and weight loss drugs over the past few years. This has increasingly led investors to view pharma stocks as a promising growth industry after years of underperformance, but many are top pharma stocks to sell.Pharma remains a tricky field where intense competition and limited product patent lives curtail profitability. Particularly in the case of these three pharma stocks to sell, investors have built up expectations substantiall ...

  Designation is based on preliminary safety and efficacy data from an ongoing Phase 1/2 trial in patients with platinum-resistant ovarian epithelial cancer, fallopian tube, or primary peritoneal cancer1Fast Track designation can facilitate the development and expedite the regulatory review of BNT325/DB-1305 Ovarian cancer is the fourth most common gynecological tumor type2 with over 300,000 cases diagnosed globally each year3; over 90% of ovarian tumors arise from epithelial cells, including the epithelia ...

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In BioNTech To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $100,000 investing in BioNTech stock or options between March 30, 2022 and October 13, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/BNTX.Th ...

The pivotal Phase 3 trial with BNT323/DB-1303 follows positive Phase 1/2 safety and efficacy data in patients with Human Epidermal Growth Factor Receptor 2 ("HER2")-expressing advanced solid tumors with early signs of anti-tumor activity in heavily pretreated patients with HER2-low and HER2-positive breast cancerThe trial is expected to enroll 532 patients with Hormone Receptor-positive ("HR+") and HER2-low metastatic breast cancer progressing on hormone therapy at clinical trial sites worldwide, initially ...

SHANGHAI, Jan. 10, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that its Research Service Unit (R in CRDMO) has signed a research service agreement with BioNTech SE (Nasdaq: BNTX, "BioNTech"), a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. Under the terms of the agreement, WuXi Biologics leverages its proprietary antibody discover ...

BioNTech SE (NASDAQ:BNTX) 42nd Annual J.P. Morgan Healthcare Conference January 9, 2024 12:00 PM ET Company Participants Ugur Sahin - CEO Ryan Richardson - Chief Strategy Officer Conference Call Participants Jess Fye - J.P. Morgan Jess Fye Great. Good morning, everyone. My name is Jess Fye. I am a Senior Biotech Analyst at J.P. Morgan, and we’re continuing the conference today with BioNTech. I am joined by the company's CEO, Dr. Ugur Sahin. He is going to give a presentation on the company and then we are g ...

BioNTech SE (NASDAQ:BNTX) 42nd Annual J.P. Morgan Healthcare Conference January 9, 2024 12:00 PM ET Company Participants Ugur Sahin - CEO Ryan Richardson - Chief Strategy Officer Conference Call Participants Jess Fye - J.P. Morgan Jess Fye Great. Good morning, everyone. My name is Jess Fye. I am a Senior Biotech Analyst at J.P. Morgan, and we’re continuing the conference today with BioNTech. I am joined by the company's CEO, Dr. Ugur Sahin. He is going to give a presentation on the company and then we are g ...

Plans to have ten or more potentially registrational trials by the end of 2024 Preparing to be commercial-ready by the end of 2025 Ended 2023 with approximately €17.5 billion (unaudited) in cash, cash equivalents and security investments Expects full year 2024 revenues of approximately €3 billionPresentation and webcast at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 6:00 p.m. CET/ 12:00 p.m. ET Mainz, Germany, January 9, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX ...

Marcin Klapczynski/iStock via Getty Images At a Glance In my previous analysis of Germany-based BioNTech (NASDAQ:BNTX), I underscored its potential for growth in immunotherapy and the importance of its oncology-focused initiatives. Since then, while their COVID-19 vaccine sales have declined further, the company has made notable progress in diversifying its portfolio. This is evident in their strategic expansion into antibody-drug conjugates (ADCs) and the acquisition of MediLink Therapeutics' ADC techn ...